Table 9.
HA-Based Biopolymeric Drug Delivery Systems for Cancer Therapy
| Type of HA | Loaded Drugs | Type of Nanosystem | Zeta Potential (mV) | Diameter (nm) | PDI | Drug Release (%) | Aimed Cancer/Cell | Ref |
|---|---|---|---|---|---|---|---|---|
| HA-APMA | DOX | Nanorods | / | length: 50 ± 4, width: 10 ± 2 | / | 48h, <10% % at pH 7.4, ~30% at pH 5.5 without hyaluronidase, 8.5% at pH 7.4,46.8% at pH 5.5 with hyaluronidase | Ovarian cancer cells | [251] |
| HA | CUR | NPs | 18.10±1.08 | 184.1 ± 13.2 | 0.432 | 10h, 16.7% at pH 7.4, 30.6% at pH 5.5 |
Breast cancer | [252] |
| DAHA | DOX | Nanorods | −16.6 | Length: 55.6, Diameter:13.7 | / | 48h, without NIR, 15% at pH 7.4, 35.3% at pH 6.5, 60% at pH 5.5; with NIR radiation 27% at pH 7.4, 52.95% at pH 6.5, 78% at pH 5.5 | Breast cancer, MCF-7 | [253] |
| HA | DOX | Nanocubes | −17.60±0.98 | 149.22 ± 26.15 | / | 72h, 78% at pH 5.5,39% at pH 7.4 | HCC | [254] |
| PEG-HA | MTX | NPs | 338 | 72h, 44.12% at pH 7.4, 87.7% at pH 5 |
MDA-MB-231 and MCF-7 | [255] | ||
| HA/Catechol-modified chitosan | DOX | NPs | −12.7 ± 0.12 | 160 | 0.3 ± 0.01 | / | Oral cancer, HN22 | [256] |
| HA/Lf | Lenalidomide | NPs | 31.7 ± 1.9 | 27.4 ± 2.7 | 0.239 | 12h, 9.5% ± 1.7% at pH 7.4, 12.2% ± 2.9% at pH6.5, 24.4% ± 2.4% at pH 5.5, 19.3% ± 2.9% at pH 4.8 | U87MG | [257] |
| HA-SH | Ovalbumin | Vaccines | −27.23 mV | 175.57 | 0.2 | / | EG.7-OVA tumor-bearing mice | [258] |
| HA-CpG | DOX | NPs | −21.4 | 15.9 | / | / | Glioblastoma | [259] |
| HA, GO | DOX | NPs | −22.45 ± 1.22 | 143.7 ± 3.9 | / | at pH 7.4, GSH 10m, 48h ~28%. Without GSH, PH7.4,48h 10%, PH5.5,48h 25% In the presence of HAase, PH7.4 released ~20%, in the presence of HAase and GSH 10mM, PH7.4 released 45%, in the presence of HAase, PH 5.5 released 55% |
MDA-MB-231 | [260] |
| HA-NH2 | PFOB@IR825-HA-Cy5.5 NPs | NPs | 22.9 ± 1.8 | 80~ 110 | / | / | HT-29 | [261] |
| HA/Liposome | Epalrestat (EPS) and DOX | NPs | −10.9 ± 0.51 | −10.9 ± 0.51 | 0.119 ± 0.048 | / | TNBC | [262] |
| TPGS/hyaluronic acid dual-functionalized PLGA | Paclitaxel | NPs | −19.40 ± 0.79 | 162.30 ±1.80 | 0.15 ± 0.01 | / | TNBC and Melanoma | [263] |
| HA-Zein | CUR | NGs | ~-50 | 200 ~250 | ~0.3 | 4 days released 79% | CT26 | [117] |
| HA-NO3 | PTX/ICG | NPS | 37.9 ± 0.352 | 195.6 ± 3.2 | 0.181 ± 0.012 | / | Breast cancer | [264] |
| HA, Liposome |
DOX | NPS | −28.9 | 165 | 0.15 ± 0.03 | 48h released less than 35% at PH7.4 | Osteosarcoma | [265] |
| HA | DOX | NGs | −30.12 ± 3.12 | 52.4 ± 3.4 | / | After 24 h, 20% and 26% were released in the absence of GSH, pH 7.4 and 5.0, respectively, and 69% and 76% were released in the presence of GSH (10 mM), pH 7.4 and 5.0, respectively. | Human prostate cancer, H22 A549 /NIH3T3 | [243] |
| HA, zein | Honokiol | NGs | −34.54 ± 2.8 | 200 | / | After 48h, Zein-HNK released 80.1% and HA-Zein-HNK released 77.5% | Breast cancer, 4T1 | [118] |
| AHA, HECS | DOX and cisplatin | NGs | −28 | 160 | / | After 24 h, DOX was released 51.2% at PH5.5 and 12.45% at PH7.4, CDDP was released 57.68% at PH5.5 and 25.87% at PH7.4. | Breast cancer | [266] |
| GA, HA | DOX | NGs | −26.4±1.1 | 235.9±4.1 | 0.110±0.042 | The cumulative release time was 48h, 29% at pH 7.4,35% at pH 6.5,51% at PH5.5 | Liver cancer | [247] |
Abbreviations: DAHA, Aldehyde/catechol-functionalized hyaluronic acid; HCC, hepatocellular carcinoma; Lf, lactoferrin; GA, glycyrrhetinic acid; AHA, Aldehyde hyaluronic acid; HECS, hydroxyethyl chitosan; GO, Graphene oxide.